|OliX to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention|
|Date : 2022-06-13 View : 780|
OliX Pharmaceuticals to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention
SUWON, South Korea-- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will participate in one-on-one partnering meetings at the 2022 BIO International Convention, being held in-person from June 13 to 16, 2022.
Dong Ki Lee, Ph.D., Founder and Chief Executive Officer, and June Park, Ph.D., Head of R&D at OliX Pharmaceuticals, will meet global industry experts to discuss platform-based early discovery collaborations as well as global licensing options for the Company’s pipeline programs.
The main treatment programs of OliX include OLX101A for hypertrophic scars which the Company has recently completed patient enrollment for, OLX104C for androgenic alopecia (hair loss), OLX301A for dry and wet age-related macular degeneration (AMD), OLX702A for nonalcoholic steatohepatitis (NASH), and OLX703A for hepatitis B virus (HBV).
To schedule a meeting, please visit the 2022 BIO International Convention here.
|Prev||OliX Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease|
|Next||OliX Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypert|